随着全球医药投融资市场逐步回暖,国内创新药行业支持政策持续加码,新药研发浪潮再度兴起,医药产业“卖水人”的CXO(医药外包服务)产业趋势也向。2025年,多家CXO企业预计交出亮眼成绩单。如药明生物于2月11日发布公告称,2025全年度收益将增长约16.7%至人民币217.90亿元;2025全年度的利润及归属于公司权益股东的利润将分别增长约45.3%至人民币57.33亿元及约46.3%至人民币...
Source Link随着全球医药投融资市场逐步回暖,国内创新药行业支持政策持续加码,新药研发浪潮再度兴起,医药产业“卖水人”的CXO(医药外包服务)产业趋势也向。2025年,多家CXO企业预计交出亮眼成绩单。如药明生物于2月11日发布公告称,2025全年度收益将增长约16.7%至人民币217.90亿元;2025全年度的利润及归属于公司权益股东的利润将分别增长约45.3%至人民币57.33亿元及约46.3%至人民币...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.